Zoom in on Dementia & Alzheimer's

Zoom in on Dementia & Alzheimer's is a monthly virtual discussion series with medical experts to keep you informed about the latest breakthroughs and findings in the field—from treatments and genetics to risk reduction, supplements, and more.

 

Each session will include a live Q&A where you can ask your questions directly of the experts. All sessions will be recorded and available to watch on demand.

Zoom in on Dementia & Alzheimer's - A free virtual discussion with medical experts.

Register for upcoming Zoom in on Dementia & Alzheimer's programs

Hand holding a pen pointing at a series of brain scan images.

Risk Reduction Through Non-drug Interventions

Thursday, March 21, 2024
1:00 pm EST (please adjust for your time zone)

Featuring:

TBD

 

Previous Episodes

Marwan Noel Sabbagh MD, FAAN
February 15, 2024

Listen to world-renowned Alzheimer’s expert Dr. Marwan Sabbagh as he guides us through the complex stages and progression of Alzheimer’s and helps us understand the resources available at each stage.

 

 

Jeffrey Cummings, MD, ScD
January 25, 2024

In 2023, there were 184 trials assessing 143 drugs for the treatment of Alzheimer's disease (AD) and Mild Cognitive Impairment, with more than 60,000 participants required to populate those registered trials at 5684 sites. What is happening in 2024? Find out with Dr. Jeffrey Cummings for the insider’s overview.

 

Reisa Sperling, MD
November 16, 2023

Three new drugs for Alzheimer’s disease have been approved, and pharmaceutical companies are currently testing 141 Alzheimer’s drugs in 178 clinical trials. World-renowned expert Dr. Reisa Sperling discusses what might be coming through the treatment pipeline for dementias within the next three years.

 

Richard S. Isaacson, MD
October 19, 2023

There is no wonder drug or miracle cure for Alzheimer’s and related dementias, but research studies show that lifestyle choices can cut down your risk. Join Dr. Richard S. Isaacson as he shares insights on how preventative lifestyle changes and individualized care can meaningfully reduce your dementia risk and benefit your overall health.

 

Randall Bateman, MD
September 25, 2023

From written evaluations to blood tests, retinal and brain scans, AI-based wearable technologies, and everything in between, Dr. Randall J. Bateman takes a deep dive into the latest and greatest methods that can lead to earlier detection of dementias.

 

Cynthia Lemere, PhD
July 27, 2023

Join Dr. Cynthia Lemere, Scientist at Brigham and Women’s Hospital and Associate Professor of Neurology at Harvard Medical School, and host Nancy Lynn of BrightFocus Foundation for a discussion on the rapidly evolving—and complex—landscape of available treatments for Alzheimer’s disease and ask the experts what this means for you or a family member.

 

John Hardy, PhD
June 22, 2023

Learn about the role that genes play in the risk of developing the early- and late-onset forms of Alzheimer’s disease. Dr. John Hardy, chair of molecular biology of neurological disease at University College London Institute of Neurology, and host Nancy Lynn discuss the impact of family history on Alzheimer’s disease.

 

Malú Gámez Tansey, PhD
May 18, 2023

Learn about frontotemporal dementia (FTD), a form of dementia, and how it differs from Alzheimer’s disease. Dr. Malú Gámez Tansey, professor of neuroscience and neurology at the University of Florida, and host Nancy Lynn discuss the signs, symptoms, and stages of FTD.

 

Dr. Sharon Cohen
April 20, 2023

Learn about Leqembi, a new anti-amyloid treatment for Alzheimer's disease that received conditional approval from the FDA in January 2023. Dr. Sharon Cohen, neurologist and medical director at Toronto Memory Program, and host Nancy Lynn discuss the drug's benefits, availability, potential side effects, cost, and more, as well as other drugs in development for Alzheimer's.

 

This program is supported in part by educational grants from:

Eli Lilly logo Genentech logo

BrightFocus Foundation is dedicated to reaching millions of people worldwide through its public outreach and education efforts around brain and eye health.